PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-66.50%
Negative net income growth while VET stands at 57.72%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-0.85%
Negative yoy D&A while VET is 10.94%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
89.98%
Well above VET's 10.81% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
72.53%
Slight usage while VET is negative at -196.19%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.53%
Some yoy usage while VET is negative at -196.19%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
65.57%
Some yoy increase while VET is negative at -6125.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
36.66%
Operating cash flow growth above 1.5x VET's 19.98%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-11.37%
Negative yoy CapEx while VET is 100.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-127.67%
Both yoy lines negative, with VET at -189.08%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-447.60%
Both yoy lines negative, with VET at -266.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-70.02%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
2.34%
We slightly raise equity while VET is negative at -70.18%. John Neff sees competitor possibly preserving share count or buying back shares.
50.69%
Buyback growth of 50.69% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.